VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RDY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RDYDr. Reddy's Laboratories Limited
$14.79$12.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRDYBalance Sheet

Dr. Reddy's Laboratories Limited (RDY) Balance Sheet

26Y historyFree accessUpdated daily

Total debt more than doubled from $30.7B to $72.6B over ten quarters, lifting debt-to-equity from 0.10 to 0.19 and goodwill from $4.2B to $13.0B, while the current ratio declined from 2.55 to 1.93, suggesting an acquisition-driven capital structure shift that warrants closer examination of impairment risk.

Income StatementBalance SheetCash FlowRatios

RDY Balance Sheet

Annual statement

RDY Balance Sheet

Dr. Reddy's Laboratories Limited (RDY) balance sheet — 26-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01
Total Current Assets298.88B296B250.11B248.05B204.25B181.86B2.03B1.72B114.5B109.64B100.38B119.69B119.84B103.75B857.13B69.95B47.59B42.06B39.01B34.62B37.56B20.14B18.35B15.7B15.08B11.87B5.29B
Cash & Short-Term Investments76.58B86.08B57.91B81.47B61.8B44.37B472.87M340.25M24.76B20.97B18.14B39.95B39.65B33.53B220.99B18.15B5.76B10.76B6.13B12.15B18.04B3.74B9.6B6.93B7.25B5.1B477.24M
Cash Only13.35B15.06B14.65B7.11B5.78B14.85B202.82M27.14M2.23B2.64B18.14B39.95B39.65B33.53B51.36B18.15B5.73B6.58B5.6B7.4B18.02B3.72B9.29B4.39B7.25B5.1B477.24M
Short-Term Investments63.22B71.01B43.25B74.36B56.02B29.51B270.04M313.11M22.53B18.33B0000169.63B033M4.17B530M4.75B15.38M14.75M310.87M2.54B000
Accounts Receivable101.84B99.22B109.79B95.34B83.2B80.27B843.66M816.3M46.63B50.2B45.74B48.6B48.59B41.02B38.55B30.04B22.44B15.79B19.66B6.9B7.68B4.81B3.59B3.76B3.61B3.83B2.39B
Days Sales Outstanding123.84102.45123.1124.65123.51136.66120.491.71110.63129.01118.56114.67119.69113.29121.02113.33109.6682.02103.3350.3442.9772.2267.2468.2173.1284.179.92
Inventory81.54B75.02B71.08B63.55B48.67B50.88B621.11M463.52M33.58B29.09B28.53B25.58B25.53B23.99B216B19.35B16.06B13.37B13.23B11.13B7.56B6.91B3.5B3.04B2.77B2.19B1.91B
Days Inventory Outstanding172.22164192.04200.74166.75184.71180.232.1174.04161.55166.73149.55148.41155.351.42K162.63170.25143.81146.55165.280.48202.66136.09118.4129.51116.6122.14
Other Current Assets38.92B35.69B4.56B2.94B6.41B5.2B74.4M90.68M15.35B18.21B14.93B12.17B13.9B12.65B2.94B1.12B2.17B2.44B004.41B4.68B1.67B1.72B1.26B744.69M504.57M
Total Non-Current Assets278.12B271.88B242.88B139.47B117.6B110.97B1.6B1.35B110.93B115.96B119.45B87.96B74.92B66.48B566.56B49.52B47.41B38.27B44.78B50.82B48.57B48.8B10.94B10.97B7.94B7.08B6.55B
Property, Plant & Equipment115.6B113.63B97.76B76.89B66.46B62.17B781.13M691.75M54.09B57.87B57.16B53.96B48.09B44.42B378.14B33.25B29.64B22.46B20.88B16.77B12.46B9.11B7.06B6.34B4.82B3.79B3.23B
Fixed Asset Turnover2.88x3.11x3.33x3.63x3.70x3.45x3.27x252.40x2.84x2.45x2.46x2.87x3.08x2.98x0.31x2.91x2.52x3.13x3.33x2.98x5.24x2.67x2.76x3.17x3.74x4.38x3.38x
Goodwill13.04B12.64B11.81B4.25B4.25B4.42B62.48M52.79M3.9B3.94B3.75B3.85B3.38B3.43B31.93B2.21B2.18B2.17B7.3B16.98B15.58B16.68B00000
Intangible Assets104.62B102.98B96.8B36.95B30.85B27.25B487.57M365.61M44.37B44.66B44.92B20.8B13.05B11.27B108.28B11.32B13.07B11.8B14.88B16.62B18.93B17.08B2.59B2.67B2.86B2.86B2.88B
Long-Term Investments58.24B16.04B15.2B5.25B5.36B7.99B115.59M63.82M3.34B4.65B6.84B3.3B3.85B806M6.81B368M313M310M262M00000000
Other Non-Current Assets5.24B4.59B2.79B5.35B3.49B948M11.41M11.16M1.06B1.2B1.19B1.06B762M495M37.74B417M276M243M200M457.88M1.6B5.94B1.29B1.96B265.97M422.61M440.46M
Total Assets577B567.88B492.99B387.52B321.85B292.83B3.63B3.07B225.43B225.6B219.82B207.65B194.76B170.22B1.42T119.48B95B80.33B83.79B85.45B86.12B68.95B29.29B26.68B23.03B18.95B11.84B
Asset Turnover0.58x0.62x0.66x0.72x0.76x0.73x0.70x56.88x0.68x0.63x0.64x0.75x0.76x0.78x0.08x0.81x0.79x0.87x0.83x0.59x0.76x0.35x0.66x0.75x0.78x0.88x0.92x
Asset Growth %49.39%15.19%27.22%20.4%9.91%7964.18%18.28%-98.64%-0.08%2.63%5.86%6.62%14.42%-88.04%1091.6%25.76%18.27%-4.13%-1.93%-0.79%24.91%135.4%9.79%15.86%21.53%60.02%-
Total Current Liabilities155.17B164.25B130.39B96.04B85.84B94.02B1.14B962.5M59.7B69.69B85B64.65B63.99B54.06B536.46B43.46B41.02B29.02B26.55B19.39B18.58B18.79B7.58B4.58B3.09B2.36B4.5B
Accounts Payable36.24B32.75B20.05B21.55B17.86B15.97B173.65M142.03M10.3B9.21B000009.5B8.48B9.32B5.99B5.43B4.77B3.65B1.42B2.18B1.68B1.12B681.87M
Days Payables Outstanding80.2671.654.1768.0661.1857.9750.390.6453.3751.14-----79.8589.9100.2666.3480.5350.72106.9755.0584.9178.4759.6543.55
Short-Term Debt60.86B63.85B38.05B12.72B11.19B27.08B328.38M274.92M16.32B25.56B43.74B22.72B28.82B23.9B24.05B15.84B18.3B9.31B9.57B6.68B3.67B10.08B2.8B474.27M289.29M105.64M2.94B
Deferred Revenue (Current)3.52B01.98B1.44B1.98B2.58B27.81M25.25M1.35B982M819M659M1.06B678M553M39M503M29M1.93B587.38M557.79M173.75M236.93M152.22B166.51B695.29M382.02M
Other Current Liabilities55.25B63.43B13.52B11.42B9.19B6.76B515.05M447.37M9.21B11.04B8.91B10.91B24.43B7.97B487.5B6.04B5.36B2.49B10.37B3.13B6.17B1.8B988.95M675.53M357.01M435.81M494.09M
Current Ratio1.93x1.80x1.92x2.58x2.38x1.93x1.78x1.79x1.92x1.57x1.18x1.85x1.87x1.92x1.60x1.61x1.16x1.45x1.47x1.79x2.02x1.07x2.42x3.43x4.87x5.03x1.18x
Quick Ratio1.40x1.35x1.37x1.92x1.81x1.39x1.23x1.31x1.36x1.16x0.85x1.46x1.47x1.48x1.20x1.16x0.77x0.99x0.97x1.21x1.61x0.70x1.96x2.77x3.98x4.10x0.75x
Cash Conversion Cycle215.81194.86260.97257.33229.08263.39250.333.16231.3239.42-----196.11190.01125.57183.5413572.74167.92148.29101.69124.15141.05158.51
Total Non-Current Liabilities30.75B30.7B25.43B10.93B5.02B8.29B123.62M58.68M25.53B29.45B10.78B14.67B19.46B25.36B156.18B18.57B8B8.39B15.19B18.99B25.86B27.82B753.28M1.02B1.15B1.15B2.11B
Long-Term Debt11.74B11.96B3.8B3.8B03.8B51.97M021.45B24.46B4.85B9.94B14.31B19.79B11.83B16.07B5.32B5.38B012.86B17.91B20.99B25.15M31.15M40.81M46.97M999.73M
Capital Lease Obligations23.49B04.06B2.19B1.28B1.95B34.18M17.24M552M630M597M747M775M947M796M260M00000000000
Deferred Tax Liabilities62.5B15.26B14.11B909M833M60M4.62M3.64M610M730M1.2B767M1.78B2.74B1.98B1.13B2.02B2.72B4.67B5.64B7.57B6.36B551.79M572.8M698.25M657.18M861.73M
Other Non-Current Liabilities2.75B3.48B2.3B2.84B1.35B882M11.9M11.95M918M4.36B5.33B3.98B4.38B4.62B143.56B1.11B662M288M10.48B458M284.33M412.97M118.08M412.54M414.03M443.42M244.95M
Total Liabilities185.92B194.95B155.82B106.97B90.86B102.3B1.26B1.02B85.23B99.14B95.78B79.31B83.46B79.42B692.64B62.03B49.02B37.41B41.75B38.38B44.44B46.62B8.34B5.59B4.25B3.51B6.6B
Total Debt72.6B75.81B46.77B20.02B13.47B33.84B414.53M292.16M38.38B50.71B49.19B33.51B43.13B44.74B367.6B32.21B23.62B14.7B19.7B19.54B24.81B31.08B2.83B505.42M330.09M152.61M3.94B
Net Debt59.25B60.75B32.11B12.91B7.69B18.99B211.71M265.02M36.15B48.08B31.05B-6.44B3.47B11.21B316.23B14.06B17.89B8.11B14.11B12.14B6.79B27.35B-6.46B-3.88B-6.92B-4.95B3.46B
Debt / Equity0.19x0.20x0.14x0.07x0.06x0.18x0.18x0.14x0.27x0.40x0.40x0.26x0.39x0.49x0.50x0.56x0.51x0.34x0.47x0.42x0.60x1.39x0.13x0.02x0.02x0.01x0.75x
Debt / EBITDA1.42x1.07x0.53x0.24x0.19x0.82x0.03x0.01x1.16x2.15x1.99x0.84x1.25x1.35x13.79x1.37x1.41x2.38x20.10x2.04x1.74x10.30x3.00x0.16x0.08x0.03x1.66x
Net Debt / EBITDA1.16x0.86x0.36x0.16x0.11x0.46x0.02x0.01x1.09x2.03x1.25x-0.16x0.10x0.34x11.86x0.60x1.07x1.32x14.39x1.27x0.48x9.07x-6.85x-1.21x-1.59x-0.82x1.46x
Interest Coverage7.16x15.66x28.14x43.00x43.27x34.71x0.37x2114.41x26.25x19.20x24.11x33.86x26.79x21.88x22.29x18.31x35.01x6.52x-1.40x3.65x-------
Total Equity391.08B372.92B337.17B280.55B230.99B190.53B2.37B2.05B140.2B126.46B124.04B128.34B111.3B90.8B731.04B57.44B45.99B42.91B42.05B47.07B41.69B22.33B20.95B21.08B18.78B15.44B5.24B
Equity Growth %44.79%10.61%20.18%21.45%21.24%7949.22%15.54%-98.54%10.86%1.95%-3.34%15.3%22.58%-87.58%1172.62%24.91%7.17%2.07%-10.67%12.9%86.69%6.57%-0.63%12.29%21.61%194.81%-
Book Value per Share469.29447.55404.13336.58277.66229.082.852.47168.71152.19148.56150.04130.23106.39857.8767.5154.1250.6049.9555.8052.3529.1127.3727.5424.5420.288.29
Total Shareholders' Equity387.87B369.6B333.39B280.55B230.99B190.53B2.37B2.05B140.2B126.46B124.04B128.34B111.3B90.8B730.85B57.44B45.99B42.91B42.05B47.07B41.68B22.33B20.95B21.08B18.78B15.44B5.22B
Common Stock838.66M818.47M834M834M833M832M11.38M10.98M830M830M829M853M852M851M8.49B848M846M844M842M840.88M841.53M384.46M382.58M383.43M381.47M382.17M314.75M
Retained Earnings360.58B345.02B315.79B265.26B215.59B175.71B2.13B1.91B128.65B113.86B108.22B99.55B83.64B65.05B44.81B31.6B20.39B18.04B18.3B24.03B20.14B11.23B10.01B10.25B8.3B4.98B624.83M
Treasury Stock-1.49B-1.78B-2.26B-991M-1.27B-1.6B-26.9M-13.3M-535M0000000000-4.88M00-10.09B0000
Accumulated OCI16.42B10.5B3.98B653M886M755M127.02M32M3.04B3.98B7.8B5.33B4.63B3.35B722.36B865M002.17B2.16B740.48M425.76M472.1M338.66M41.33M3.36M1.26M
Minority Interest3.2B3.33B3.78B00000000000192M0000010.5M0000015.92M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowDeteriorating
Top Statement Risk

Goodwill impairment amid rising leverage

Debt Doubling Amid Cash Flow Stress

Total debt has more than doubled from $30.7B in 2025Q1 to $72.6B by 2027Q2, lifting the debt-to-equity ratio from 0.10 to 0.19. The concurrent goodwill surge suggests leverage was deployed for acquisitions rather than necessity, though deteriorating operating cash flow complicates repayment capacity.

The 136% increase in total debt from $30.7B to $72.6B coincides closely with the goodwill revaluation from $4.2B to $11.8B, strongly suggesting acquisition-related borrowing rather than operational financing. However, prior cash flow analysis documented a collapse in operating cash flow to negative $927M in 2027Q1 and a cumulative OCF/NI ratio of approximately 0.79 over the period, meaning the company's ability to service this elevated debt load from internal cash generation has weakened materially even as the headline leverage ratio of 0.19 remains low by industry standards. The concern is not nominal leverage but the divergence between rising obligations and a cash generation profile that has turned negative in recent quarters. Investors should monitor whether debt continues to climb without a corresponding recovery in operating cash flow, as the current trajectory could shift leverage from strategic to necessity-driven.

Cash Volatility Thins Liquidity Buffer

Dr. Reddy's current ratio declined from 2.55 to 1.93 over ten quarters, while cash reserves swung between $4.9B and $18.7B before settling at $13.4B in 2027Q2. This pattern, combined with documented working capital consumption, suggests a structurally thinner liquidity buffer against near-term operational shocks.

The current ratio compression from 2.55 to 1.93 reflects a structural shift rather than a temporary fluctuation, as it has trended consistently downward even as absolute cash balances fluctuated with working capital timing. With working capital consuming $21.9B across 2027Q1 and 2027Q2 per the cash flow analysis, the liquidity position appears increasingly dependent on the timing of receipts and inventory liquidation rather than a stable cash reserve. The $13.4B cash position at 2027Q2 represents only approximately 18% of total debt, suggesting limited flexibility if operational cash generation continues to disappoint. While the current ratio above 1.9 remains above distress levels, the trajectory indicates that the buffer is eroding in tandem with deteriorating free cash flow, warranting close monitoring of near-term working capital management.

Acquisition-Driven Asset Expansion Elevates Risk

A dramatic goodwill revaluation from $4.2B to $11.8B between 2025Q1 and 2025Q2 signals a transformative acquisition, while net PPE expanded 44% to $115.6B, indicating concurrent organic capital investment that has materially increased the asset base's sensitivity to pricing pressure and impairment risk.

The goodwill step-up is the single most significant structural change in the asset base, indicating a major acquisition whose integration outcomes are not yet visible in the deteriorating operating margins documented in the income statement analysis. Meanwhile, PPE growth of 44% from $80.3B to $115.6B suggests aggressive capacity expansion, but with gross margins compressing 830 basis points and revenue contracting, the return on these invested assets appears increasingly questionable. The asset mix is becoming more capital-intensive at precisely the moment when pricing power is eroding, which could result in future impairment charges if the acquired business or newly expanded capacity fails to generate adequate returns. This structural shift in asset composition deserves closer scrutiny than the headline asset growth figure suggests.

Leverage Shift Outpaces Equity Growth

Total assets expanded 39% from $415.3B to $577.0B over ten quarters, yet debt grew 136% against equity growth of only 32%, indicating the balance sheet's financing mix has shifted materially toward leverage even as reported profitability margins have compressed sharply.

While the headline balance sheet metrics appear healthy—assets up 39%, equity up 32%, retained earnings compounding from $279.3B to $360.6B—the underlying trajectory reveals a growing reliance on debt financing. Debt's 136% growth far outpaces the 32% equity expansion, meaning each incremental dollar of assets is increasingly debt-financed rather than equity-funded. Combined with the documented free cash flow swing from $10.8B in 2025Q4 to negative $4.6B in 2027Q1, this trajectory suggests the balance sheet's resilience is being gradually sacrificed to fund growth that has yet to produce commensurate cash returns. The retained earnings accumulation remains a positive signal of underlying profitability, but its pace is unlikely to offset the leverage shift if cash flow recovery remains elusive.

Goodwill Carrying Value Warrants Skepticism

Goodwill now represents $13.0B of total assets, and with operating margins falling from 23.4% to 13.7% and revenue contracting, the risk of impairment thresholds being approached is elevated, which could materially compress the $387.9B equity base reported in 2027Q2.

The $13.0B in goodwill represents a contingent impairment risk that headline balance sheet metrics may understate. Given the prior income statement analysis showing operating margin decline from 23.4% to 13.7% and revenue contraction in the most recent quarter, the acquired business may not be generating returns sufficient to justify its carrying value. A write-down would directly reduce the reported $387.9B equity base and could push the effective debt-to-equity ratio materially above the reported 0.19, revealing a more leveraged balance sheet than the current figures suggest. This dynamic is compounded by the earnings quality concerns identified in prior analysis, where the cumulative operating cash flow shortfall of approximately $23.7B relative to net income suggests that the accounting profits supporting goodwill valuation may not be fully cash-backed. Investors should monitor impairment disclosures closely in upcoming filings.

RDY — Frequently Asked Questions

Quick answers to the most common questions about buying RDY stock.

What are the total assets of Dr. Reddy's Laboratories Limited (RDY)?

As of 2026, Dr. Reddy's Laboratories Limited (RDY) had total assets of $567.88B including $296.00B in current assets.

How much debt does Dr. Reddy's Laboratories Limited (RDY) have?

Dr. Reddy's Laboratories Limited (RDY) carries total debt of $75.81B, offset by $86.08B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Dr. Reddy's Laboratories Limited?

Dr. Reddy's Laboratories Limited (RDY) has total shareholders' equity (book value) of $369.60B ($447.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Dr. Reddy's Laboratories Limited's current ratio and liquidity?

Dr. Reddy's Laboratories Limited (RDY) reported a current ratio of 1.80x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.